
    
      Phase I part is designed to evaluate the safety of EMD531444 930 microgram (mcg) dose to be
      used in phase II. Phase II part is designed to be conducted as randomized, double blind,
      placebo controlled study to compare overall survival time in all randomized subjects.
    
  